Navigation Links
Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
Date:7/21/2009

JERUSALEM, Israel, July 21 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com), a developer of alternative drug delivery systems, today reported positive results from a Phase 2A study of its oral insulin capsule, ORMD-0801, on type 1 diabetic patients. The completion of this study marks Oramed's first clinical trial on patients with Type 1 Diabetes Mellitus, whereas, all Oramed's trials up to date have been conducted on type 2 diabetic patients. This study evaluated safety, tolerability, and food effects in type 1 diabetic patients.

Oramed's oral insulin capsule, (ORMD-0801), was well tolerated by patients and no serious adverse events were observed. The insulin absorption was not affected when given before meal ingestion.

Oramed Chief Scientific Officer, Miriam Kidron, PhD., remarked, "These results demonstrate that Oramed's oral insulin capsule had a good safety profile and was effective on patients with type 1 diabetes when taken prior to a meal."

Currently, Oramed is conducting its Phase 2B clinical trial in South Africa, in which the company is evaluating the effects of ORMD-0801 on type 2 diabetic patients.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

    Company and Investor Relation Contacts:
    Oramed Pharmaceuticals
    Tara Horn
    USA: +1-646-240-4193
    Int'l: +972-54-334-318
    Office: +972-2-566-0001
    Email: tara@oramed.com



'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oramed Pharmaceuticals to Present at Rodman & Renshaw Healthcare Conference (November 11, 2008; NYC)
2. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
3. Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
4. Israels Prestigious Presidents Conference to Feature Oramed Pharmaceuticals Revolutionary Oral Insulin Capsule
5. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
6. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
7. VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
8. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
9. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
10. Amylin Pharmaceuticals to Webcast Second Quarter Results
11. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... LONDON and NEW YORK ... at HIMSS, Lumeon , a leading digital ... (DN Telehealth), a provider of telemedicine and remote ... care pathways for telemedicine reimbursements.  ... and their patients, in real-time, extending consultations beyond ...
(Date:2/23/2017)... JOSE, Calif. , Feb. 23, 2017 /PRNewswire/ ... exclusive license for two key immunotherapy technologies from ... first technology provides a method to monitor a ... such as PD-L1 and CTLA-4.  The second license ... if a patient is likely to have an ...
(Date:2/23/2017)... ... February 23, 2017 , ... Brain Sentinel, Inc. has ... the SPEAC® System, the Brain Sentinel® Seizure Monitoring and Alerting System. The adjunctive ... during periods of rest. A lightweight, non-invasive monitor is placed on the belly ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Greater Gift ... new partnership with Compass Research . GGI's mission is to advance global health ... a child in need in honor of each clinical trial volunteer. The vision of ...
Breaking Biology Technology:
(Date:2/7/2017)... , Feb. 7, 2017   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... , its innovative, highly flexible and award winning eClinical ... customers. iMedNet is a proven Software-as-a-Service (SaaS) ... Data Capture (EDC), but also delivers an entire suite ...
(Date:2/6/2017)... According to Acuity Market Intelligence, ongoing ... to continue to embrace biometric and digital identification ... Border Control (ABC) eGates and 1436 Automated Passport ... 163 ports of entry across the globe. Deployments ... combined CAGR of 37%. APC Kiosks reached 75% ...
(Date:2/2/2017)...   TapImmune, Inc. (NASDAQ: ... the development of innovative peptide and gene-based immunotherapeutics ... metastatic disease, announced today it has successfully completed ... second clinical lot of TPIV 200, the company,s ... manufactured vaccine product will be used to supply ...
Breaking Biology News(10 mins):